Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis

Research Site, Brno

Research Site, Hraddec Kralove

Research Site, Olomouc

Research Site, Pilsen

Research Site, Prague

Research Site, Teplice

Research Site, Bayreuth

Research Site, Erlangen

Research Site, Marburg

Research Site, Osnabrück

Research Site, Regensburg

Research Site, Rostock

Research Site, Budapest

Research Site, Debrecen

Research Site, Esztergom

Research Site, Győr

Research Site, Kecskemét

Research Site, Miskolc

Research Site, Nyíregyháza

Research Site, Siófok

Research Site, Zalaegerszeg

Research Site, Andra-Pradeash

Research Site, Bangalore

Research Site, Jaipur

Research Site, Kolkata

Research Site, Mumbai

Research Site, Visakhapatnam

Research Site, Bialystok

Research Site, Gdansk

Research Site, Katowice

Research Site, Krakow

Research Site, Lodz

Research Site, Lublin

Research Site, Warsaw

Research Site, Kazan'

Research Site, Krasnoyarsk

Research Site, Moscow

Research Site, Nizhny Novgorod

Research Site, Novosibirsk

Research Site, Omsk

Research Site, Saint Petersburg

Research Site, Samara

Research Site, Smolensk

Research Site, Ufa

Research Site, Yaroskavl

Research Site, Chernivtsi

Research Site, Dnipropetrovsk

Research Site, Donetsk

Research Site, Kharkiv

Research Site, Kiev

Research Site, Lviv

Research Site, Poltava

Research Site, Zaporizhzhya

Research Site, Devon

Research Site, London

Research Site, Nottingham

Research Site, Sheffield

Research Site, Stoke-on-Trent